Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$22.80 USD
+0.59 (2.66%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $22.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Corcept Therapeutics Incorporated [CORT]
Reports for Purchase
Showing records 201 - 218 ( 218 total )
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Discontinuation of Coverage of the Biotech Sector
Provider: Brinson Patrick Securities Corporation
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Two Data Readouts in 1H15; Reiterating Market Outperform
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Reports 2Q14 EPS; Advancing CORT-125 in August
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Reports 1Q14 EPS; Lowering Price Target to $6
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Orphan Drug Play with Significant Upside Potential
Provider: BRINSON PATRICK SECURITIES CORPORATION